CGDG holdings

Computed by this site from the fund's SEC Form N-PORT filing; what the measure does not tell you · every fund in one table · hold it with other funds? X-ray the mix. Pricing: 100% at a quoted market price (level 1), 21 issuer countries, 1.51% restricted securities.

CGDG's largest investment is Broadcom Inc at 4.63% of net assets. Taiwan Semiconductor Manufacturing Co Ltd and Philip Morris International Inc follow; the three together are 12.57%. Ten companies are 26.1% of the fund; the other 92 share the rest. Among the 721 equity funds measured here, CGDG behaves like 68.4 holdings against a median of 42.4 — 1.6 times the median. Across 11 quarterly filings CGDG has held roughly steady since 2023-11-30 (61.3 then, 68.4 now). Between the 2026-02-28 and 2026-05-31 filings 8 positions were added and 8 dropped; 12.0% of the weight moved. the United States is the largest country at 46.05% of the portfolio, across 21 countries in the filing.

Each sentence is read from the fund's own SEC filing; the class median is computed across the comparable equity funds on this site. Nothing here is a view on the fund.

Between 2023-11-30 and 2026-05-31, CGDG went from behaving like 61.3 equally weighted positions to 68.4 — 12% more, while its top ten went from 26.57% to 26.1% of net assets. Read across the funds on the concentration-over-time table.

One row per filed reporting period, newest first, read from EDGAR. Quarterly because that is the public filing cadence. Rows marked * are published but held out of the comparison above; the methodology page says when and why.

The 15 largest of 102 positions in CGDG's Form N-PORT, weight as a share of net assets, securities-lending collateral excluded. Every position, every quarter: CGDG.csv.gz.

Share of CGDG's own investments by the issuer country the filer reported (incorporation, not revenue). Each country links to every fund that holds it.

Monthly total returns from Item B.5 of CGDG's own filings, 33 months on record. Not computed here and not from a price feed.

Cross-checked against a series computed separately from prices: median difference — percentage points over 0 months, which is roughly the distributions. Every month with the filing it came from: CGDG.json · all funds.

The fund lends its holdings, and Item B.4.a of the filing names every firm holding them. At 2025-08-31, $2m was out to 1 borrower, 0.08% of net assets.

The filing reports no cash collateral position against this loan. Collateral taken in a form the fund does not hold as a position does not appear in N-PORT, so this is silence rather than absence. What the collateral figure can and cannot show. Every quarter CGDG has filed, with each borrower: CGDG.json · all funds.

102 positions became 102: 8 added (5.5% of the fund at the later date), 8 dropped (4.9% at the earlier date). Half the sum of all weight changes, a turnover proxy: 12.0%. Positions are matched on identifiers, so a security whose identifier changed shows as one drop and one add. Every filing of CGDG compared this way, as a feed: changes.xml · all funds: filings received.

New: Royalty Pharma PLC (1.07%), Roche Holding AG (0.96%), Merck & Co Inc (0.74%), BNP Paribas SA (0.70%), Hana Financial Group Inc (0.62%), Amcor PLC (0.53%). Gone: International Paper Co (0.91%), FedEx Corp (0.81%), Amcor PLC (0.76%), London Stock Exchange Group PLC (0.54%), America Movil SAB de CV (0.53%), Bristol-Myers Squibb Co (0.48%).

100.00% equity as filed; 100.0% carried at a quoted market price (fair-value level 1). Categories and levels are the filer's; what a low level-1 share does and does not mean is in the measure's page.

Every measured equity fund lined up by how many holdings it behaves like; these sit either side of CGDG (68.4). Same filings, same arithmetic. Position in this list says nothing about which fund is better.